A study presented at the Alzheimer's Association International Conference found type 2 diabetes patients treated with metformin had a five-year reduced risk of dementia compared with those on other treatments such as sulfonylureas, thiazolidinediones and insulin. "These results are preliminary evidence that benefits of insulin sensitizers may extend beyond glycemic control to neurocognitive health," researchers wrote.

Related Summaries